Xuanwu hospital capital medical university
Welcome,         Profile    Billing    Logout  
 419 Trials 
1513 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fan, Dongsheng
NCT04963985: The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients

Recruiting
4
10
RoW
Tafamidis Pill
Peking University Third Hospital
Transthyretin Amyloidosis
06/22
06/23
NCT04950972: Intravenous Administration of BIIB093 (Glibenclamide) in the Treatment of Severe Cerebral Edema After Massive Cerebral Infarction

Recruiting
3
743
RoW
BIIB093, placebo
Peking University Third Hospital, Beijing Tiantan Hospital
Large Hemispheric Infarction (LHI)
12/21
12/22
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed
3
176
RoW
PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution
Tasly GeneNet Pharmaceuticals Co., Ltd
Charcot-Marie-Tooth Type 1A
03/24
03/24
NCT04950933: The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules

Recruiting
2/3
144
RoW
Huolingshengji Granules, Riluzole tablet
Peking University Third Hospital, The Second Hospital of Hebei Medical University
Amyotrophic Lateral Sclerosis
12/21
12/22
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT04952155: Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Recruiting
2
13
RoW
IL-2
Peking University Third Hospital
Amyotrophic Lateral Sclerosis
12/21
12/22
NCT04950647: Efficacy and Safety of Nitrazine in the Treatment of ALS

Recruiting
2
150
RoW
Nitrofurazone Group 1, Nitroketazine Group 2, placebo group
Peking University Third Hospital, West China Hospital
Amyotrophic Lateral Sclerosis
07/22
12/22
NCT04953663: Clinical Plan of Ischemic Stroke

Recruiting
1/2
60
RoW
it-hMSC
Peking University Third Hospital
Stroke
01/22
01/23
NCT06493279: Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis

Not yet recruiting
1
9
NA
RJK002 Intrathecal injection
Rejukon Biopharm Inc., Peking University Third Hospital, Nanfang Hospital, Southern Medical University
Amyotrophic Lateral Sclerosis Als
11/25
05/31
ChALSR, NCT04328675: Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China

Recruiting
N/A
4752
RoW
Peking University Third Hospital
Amyotrophic Lateral Sclerosis
03/23
03/23
NCT04952246: Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis

Recruiting
N/A
150
RoW
Peking University Third Hospital
Clinical Isolation Syndrome of Spinal Cord, Multiple Sclerosis
11/20
11/23
GEMINI1, NCT04964791: RMS Study of BTK Inhibitor SAR442168

Recruiting
N/A
900
RoW
SAR442168
Peking University Third Hospital
Relapsing Multiple Sclerosis
08/21
08/24
NCT04952038: Sleep Disorders and the Onset and Progression of ALS

Recruiting
N/A
200
RoW
sleep disorder
Peking University Third Hospital
Amyotrophic Lateral Sclerosis
12/21
03/22
NCT04953624: Appetite and Related Factors in Patients With ALS

Recruiting
N/A
200
RoW
Appetite rating scale CNAQ
Peking University Third Hospital
Amyotrophic Lateral Sclerosis
12/21
03/22
NCT04957420: The Practical Effect of Neupro

Recruiting
N/A
3000
RoW
Neupro
Peking University Third Hospital
Parkinson's Disease
12/21
04/22
NCT04454892: Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)

Recruiting
N/A
3000
RoW
Amyotrophic lateral sclerosis
Peking University Third Hospital
Amyotrophic Lateral Sclerosis
12/30
12/30
Zhao, Gang
NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

Recruiting
3
688
RoW
Radical colectomy, HIPEC, Systemic chemotherapy
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University
Colorectal Cancer
04/24
04/26
NCT04152889: A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Recruiting
2
20
RoW
Camrelizumab, SHR-1210, S-1, Docetaxel
RenJi Hospital
Gastric Cancer Stage III
04/22
12/22
CLASS-03a, NCT03468712: Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers

Recruiting
N/A
166
RoW
Laparoscopic D2 distal gastrectomy
West China Hospital, Peking University Cancer Hospital & Institute, Southern Medical University, China, Shanghai Zhongshan Hospital, Chinese PLA General Hospital, Fujian Medical University Union Hospital, Ruijin Hospital, Southwest Hospital, China, RenJi Hospital, The First Affiliated Hospital with Nanjing Medical University, Fudan University, Tang-Du Hospital, Harbin Medical University, The First Hospital of Jilin University, Guangdong Provincial People's Hospital, Sir Run Run Shaw Hospital
Complications, Postoperative, Surgery--Complications, Cancer of Stomach, Chemotherapy Effect
04/20
04/23
NCT06553430: Effects of an Aerobic Exercise Intervention on Core Symptoms, Executive Functioning, and Quality of Life in Children With Attention Deficit Hyperactivity Disorder

Recruiting
N/A
50
RoW
aerobics exercises
Harbin Medical University
ADHD
10/24
11/24
NCT05947461: Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac

Terminated
N/A
1204
RoW
100mg diclofenac, 100mg indomethacin
Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis, NSAIDs, Indomethacin, Diclofenac, Endoscopic Retrograde Cholangiopancreatography
06/24
06/24
NCT04559048: Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients

Recruiting
N/A
300
RoW
FK506
The Second Hospital of Tangshan, Chinese PLA General Hospital
Chronic Pain, Liver Transplantation
03/24
06/24
NCT04440605: A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis

Recruiting
N/A
968
RoW
Preoperative staging——D2 gastrectomy——Postoperative staging
Peking University, RenJi Hospital, Ruijin Hospital, West China Hospital, Beijing 302 Hospital, Fudan University, Peking University International Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Fujian Medical University Union Hospital, First Affiliated Hospital Xi'an Jiaotong University, Chinese PLA General Hospital, First Affiliated Hospital of Xinjiang Medical University, Tianjin Medical University General Hospital, The Second Affiliated Hospital of Dalian Medical University, Wuhan Union Hospital, China, Peking University People's Hospital, Weifang People's Hospital, Second Hospital of Jilin University, Fujian Province Tumor Hospital, Shanxi Province Cancer Hospital, The First Affiliated Hospital of Nanchang University, Tianjin Medical University Cancer Institute and Hospital, Shanghai Zhongshan Hospital, First Affiliated Hospital, Sun Yat-Sen University, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Xiamen University, Beijing Hospital, Beijing Friendship Hospital, Qingdao Municipal Hospital, Guangdong Provincial People's Hospital, Affiliated Hospital of Qinghai University, Shandong Provincial Hospital, First Hospital of Jilin University, Nanfang Hospital of Southern Medical University, Zhongshan Hospital Xiamen University, Hebei Medical University Fourth Hospital
Gastric Cancer, Gastric Cancer Stage, CT, Neoadjuvant Therapy
04/22
10/22
Li, Jing
BRAVO, NCT05647915: Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

Completed
4
337
RoW
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention
China National Center for Cardiovascular Diseases
Obesity, Obesity, Abdominal, NAFLD
08/24
08/24
NCT06425120: Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Not yet recruiting
4
240
RoW
Xuesaitong Soft Capsule, LixuwangⓇ, Placebo
China National Center for Cardiovascular Diseases
Coronary Heart Disease
12/24
12/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT05965284: Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Recruiting
4
40
RoW
Azathioprine, Telitacicept, Taiai for commercial name
Chinese SLE Treatment And Research Group
ANCA-associated Vasculitis, Maintenance Therapy
12/25
12/26
ABCD, NCT05749874: Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

Not yet recruiting
4
6500
RoW
Berberine plus lifestyle intervention, Placebo plus lifestyle intervention
China National Center for Cardiovascular Diseases
PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
12/26
12/26
NCT05962840: Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Recruiting
4
40
RoW
Telitacicept, Taiai for commercial name, Placebo of Telitacicept
Chinese SLE Treatment And Research Group, Peking Union Medical College Hospital
ANCA Associated Vasculitis
12/26
12/26
EHTASEOCCS, NCT03373058: Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery

Recruiting
3
310
RoW
Hyperthermic Intraperitoneal Chemotherapy, HIPEC, cytoreductive surgery, CRS, adjuvant chemotherapy, ACT
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Henan Provincial People's Hospital, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Cancer Hospital of Guizhou Province, Chinese PLA General Hospital, Hebei Medical University Fourth Hospital, The Second Hospital of Hebei Medical University, West China Second University Hospital, Peking Union Medical College Hospital, First Affiliated Hospital, Sun Yat-Sen University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, The Third Affiliated Hospital of Guangzhou Medical University, Wuhan University, RenJi Hospital, Obstetrics & Gynecology Hospital of Fudan University, Southern Medical University, China, Fourth Affiliated Hospital of Guangxi Medical University, Shandong Cancer Hospital and Institute, Beijing Obstetrics and Gynecology Hospital, Chongqing University Cancer Hospital, Xinqiao Hospital of Chongqing, Wuhan Union Hospital, China, First Affiliated Hospital of Chongqing Medical University, Affiliated Cancer Hospital of Shantou University Medical College
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
07/21
07/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting
3
1380
RoW
Shuxuening Injection, Placebo
Beijing Tiantan Hospital
Ischemic Stroke, Acute
06/25
12/26
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting
3
1380
RoW
Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin
Beijing Tiantan Hospital
Ischemic Stroke, Acute
12/25
12/26
Be-CLEVER, NCT05976152: Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial

Recruiting
3
3200
RoW
dl-3-butylphthalide, DL-3-n-butylphthalide (NBP), dl-3-butylphthalide placebo, NBP placebo
Fudan University
Stroke, Post-stroke Cognitive Impairment (PSCI)
12/26
12/26
NCT01592968: Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases

Active, not recruiting
3
88
US
Cognitive Assessment, Quality-of-Life Assessment, Quality of Life Assessment, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
09/25
09/25
NHIPEC, NCT05246020: Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the Trial)

Recruiting
2
80
RoW
HIPEC, intravenous chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hyperthermic Intraperitoneal Chemotherapy, Neoadjuvant Chemotherapy
12/22
12/24
NCT02713269: Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases At Risk for Compressing the Spinal Cord

Active, not recruiting
2
60
US
Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Thermal Ablation Therapy, thermal ablation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Melanoma, Prostate Carcinoma Metastatic in the Bone, Sarcoma, Solid Neoplasm, Spinal Cord Compression, Stage IV Breast Cancer AJCC V6 and V7, Stage IV Lung Non-Small Cell Cancer AJCC V7, Thyroid Gland Carcinoma
08/25
08/25
NCT06205927: Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer

Recruiting
2
77
RoW
Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost
Jian Chen
Non-small Cell Lung Cancer
12/24
12/26
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT06186726: Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Recruiting
2
48
RoW
carbon ion radiotherapy
Jian Chen
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
12/26
12/29
NCT06311981: Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Recruiting
2
29
RoW
carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy
Jian Chen
Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy, Radiotherapy Side Effect
06/25
06/26
NCT06311955: Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Recruiting
2
48
RoW
Carbon ion radiotherapy, combined with platinum-based regimen
Jian Chen
Thymic Epithelial Tumor, Radiotherapy Side Effect, Carbon Ion Radiotheray, Heavy Ion Radiotherapy
02/28
02/29
NCT06311968: The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor

Recruiting
2
55
RoW
Proton radiotherapy, combined platinum based chemotherapy
Jian Chen
Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity
02/27
02/27
AGE-M, NCT06459310: Pilot Study on Evaluating the Geroprotective Effect of Metformin

Not yet recruiting
2
120
RoW
Metformin Hydrochloride tablet, Metformin, Placebo
Xuanwu Hospital, Beijing, Institute of Zoology, Chinese Academy of Sciences, Beijing Institute of Genomics, Chinese Academy of Sciences, Merck Serono Co., Ltd., China
Metformin, Aging
09/26
07/28
NCI-2018-01809, NCT01644591: Stereotactic Radiosurgery in Treating Patients with Greater Than 3 Melanoma Brain Metastases

Active, not recruiting
2
49
US
Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC V8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC V8
08/26
08/26
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease

Recruiting
2
320
RoW
SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan
Shanghai Pharmaceuticals Holding Co., Ltd
Diabetic Kidney Disease
06/25
06/25
NCT04516070: Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

Active, not recruiting
2
55
US
Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/26
12/26
NCT05613452: Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Recruiting
2
43
RoW
Carbon ion beam radiotherapy
Shanghai Proton and Heavy Ion Center
Non-small Cell Lung Cancer
01/25
01/26
NCT06036966: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Not yet recruiting
2
34
NA
Hetrombopag
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Thrombocytopenia
07/25
07/25
FRUSICA-1, NCT03903705: : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Recruiting
1/2
381
RoW
Fruquintinib in Combination with Sintilimab, Fruquintinib
Hutchmed
Advanced Solid Tumor
12/25
12/25
NCT05382910: A Study of MG-K10 in Subjects With Asthma

Recruiting
1/2
180
RoW
MG-K10, Placebo
Shanghai Mabgeek Biotech.Co.Ltd
Asthma
12/23
06/24
NCI-2016-00661, NCT02696993: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Active, not recruiting
1/2
80
US
Cognitive Assessment, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, stereotactic radiation therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
12/24
12/24
NCT04592458: Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Not yet recruiting
1
10
RoW
β-globin restored autologous HSC
BGI-research, Shenzhen Children's Hospital
β-Thalassemia Major
11/22
11/24
SAFE-APD, NCT03598387: Automated Peritoneal Dialysis Versus Intermittent Hemodialysis in Acute Kidney Injury

Recruiting
N/A
100
RoW
Automated peritoneal dialysis, Intermittent hemodialysis
Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation
Acute Kidney Injury
12/22
12/22
NCT04682795: Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

Recruiting
N/A
200
RoW
Needle-free injector, Insulin pen
Second Affiliated Hospital, School of Medicine, Zhejiang University
T2DM (Type 2 Diabetes Mellitus), Needle-free Injector, Time in Range
12/22
12/22
ESPRIT, NCT04030234: Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs () Study

Completed
N/A
11255
RoW
Intensive BP treatment group, Control of SBP to <120 mmHg, Standard BP treatment group, Control of SBP to <140 mmHg
China National Center for Cardiovascular Diseases
Hypertension
06/23
07/23
NCT05352633: Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study

Not yet recruiting
N/A
710
RoW
Intensive BP Arm, Control of SBP to <120 mmHg, Standard BP Arm, Control of SBP to <140 mmHg
China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China
Blood Pressure
09/23
09/23
PERFECT, NCT06181552: Development of CV Risk Prediction Tools Based on AI and Fundus Imaging Technology Study

Not yet recruiting
N/A
1072
NA
fundus photograpgy, optical coherence tomography, OCT, optical coherence tomography angiography, OCT-A
China National Center for Cardiovascular Diseases, Beijing Tongren Hospital
Cardiovascular Diseases
03/25
06/25
FUTURE, NCT05459519: Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease

Recruiting
N/A
165
RoW
Dengzhanxixin Capsule plus Placebo Capsule, Placebo
China National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medial Sciences, Shenzhen, Shenzhen
Diabetes, Hypertension, Hypercholesterolemia
12/23
12/23
NCT05722275: Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Recruiting
N/A
400
Europe, RoW
Peritoneal metastasis status ascertainment
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Zhenjiang First People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital of Southern Medical University, Guizhou Provincial People's Hospital, Henan Cancer Hospital, Yunnan Cancer Hospital, Guangdong Provincial People's Hospital, Guangzhou Medical University, Fujian Medical University Union Hospital, Shanxi Province Cancer Hospital, Sun Yat-sen University, Beihang University, Scientific Institute San Raffaele
Gastric Cancer, Peritoneal Metastases
12/23
12/28
NCT06422052: Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms

Recruiting
N/A
2242
RoW
Epidemiological questionnaire and Functional Dyspepsia Symptom Diary(FDSD)
Shanghai Jiao Tong University School of Medicine
Helicobacter Pylori Infection, Dyspepsia
05/25
05/25
NutriConnect, NCT06263751: Comparing the Effectiveness of Two Produce Prescription Approaches On Fruit and Vegetable Intake and Food Security, While Exploring Implementation Outcomes Such as Reach, Implementation, Sustainability, and Cost

Recruiting
N/A
240
US
Product prescription program- NutriConnect Credit, Product prescription program- NutriConnect Delivery
Washington University School of Medicine, Schnuck Markets, Inc., BJC HealthCare
Food Insecurity
03/25
06/25
NCT06163092: Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent Miscarriage

Not yet recruiting
N/A
175
RoW
Chinese University of Hong Kong
Recurrent Miscarriage
01/26
01/27
NCT05783986: Developing a MRI-based Deep Learning Model to Predict MMR Status

Not yet recruiting
N/A
600
NA
randomly divided
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University
Endometrial Cancer
06/24
12/24
NCT06622798: Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

Recruiting
N/A
470
RoW
Non-interventional
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Amoy Diagnostics Co., LTD
Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi
01/25
07/26
NCT06035250: AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Recruiting
N/A
200
Europe, RoW
Neoadjuvant Chemotherapy
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Yunnan Cancer Hospital, Henan Cancer Hospital, Zhenjiang First People's Hospital, First Hospital of China Medical University, Cancer Hospital of Guangxi Medical University, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Ruijin Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking Union Medical College Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Fujian Medical University Union Hospital, Fujian Cancer Hospital, San Raffaele University Hospital, Italy
Gastric Cancer, Image, Pathology
08/24
12/29
BLESS, NCT05397535: Baduanjin Lower Elevated Blood PreSsure Study

Recruiting
N/A
216
RoW
Baduanjin, Brisk walking
China National Center for Cardiovascular Diseases
Elevated Blood Pressure
12/24
12/25
NCT05570071: A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.

Not yet recruiting
N/A
90
NA
physical therapy
Qianfoshan Hospital
Urinary Incontinence, Stress
03/25
03/25
NCT06025045: Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments

Recruiting
N/A
50
RoW
Jing Li, Nanjing Shihejiyin Technology, Inc.
Ovarian Cancer Stage IV, Ovarian Cancer Stage III
08/25
08/25
CHAPERONE, NCT05965115: The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The Study

Recruiting
N/A
10000
RoW
Sample of Blood
Shanghai Zhongshan Hospital
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
08/25
08/35
NCT05613049: Confounding Factors of Chronic Endometritis in Women With Reproductive Failure

Recruiting
N/A
720
RoW
Chinese University of Hong Kong
IVF
07/27
01/28
NCT05153603: Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Not yet recruiting
N/A
50
NA
Olaparib mono-maintenance therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Ovarian Neoplasms
09/22
12/22
NCT04527536: Research of Diagnostic Value for BMJ Infants

Not yet recruiting
N/A
300
NA
Neonatal hyperbilirubinemia
Shanghai First Maternity and Infant Hospital
Jaundice, Neonatal
09/22
09/22
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed
4
144
Europe
Opicapone 50 mg, BIA 9-1067, Placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
02/24
02/24
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/25
07/25
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed
4
140
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo
COPD Exacerbation Acute
09/24
09/24
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Recruiting
4
150
RoW
Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences
Diarrhoea;Acute, Diarrhea Travelers
09/25
12/25
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Not yet recruiting
4
100
US
Skin Cleanser Combination No.1
Boston Children's Hospital
Atopic Dermatitis
12/28
12/28
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Not yet recruiting
4
40
US
fentanyl and Remimazolam
Indiana University, Indiana University Health
Dental Extraction
01/26
03/26
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated
4
109
US
Tamsulosin Hydrochloride
University of Massachusetts, Worcester, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
10/23
10/23
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
3
165
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
08/24
07/25
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC
Active, not recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, AstraZeneca
Non-small Cell Lung Cancer
05/24
06/25
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Small Cell Lung Cancer
04/27
02/29
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting
3
50
US
Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol
Planned Parenthood League of Massachusetts
Abortion
07/24
09/24
HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting
3
586
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
05/24
06/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Not yet recruiting
3
1500
US
Transdermal system containing progestin
Mylan Pharmaceuticals Inc
Female Contraception
03/27
04/27
VDJ001-RA-Ⅲ, NCT06726096: Phase III Trial of VDJ001 in Patients with Moderate-to-severe Active Rheumatoid Arthritis

Not yet recruiting
3
615
RoW
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Beijing VDJBio Co., LTD.
Rheumatoid Arthritis (RA)
12/25
12/26
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Not yet recruiting
3
78
Europe
Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Swedish Orphan Biovitrum, PSI CRO
Severe Haemophilia A
08/26
08/26
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Incyte Corporation
Diffuse Large B-cell Lymphoma
06/25
05/26
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting
3
110
RoW
68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET
Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
12/25
07/26
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Active, not recruiting
3
93
Europe, RoW
Efanesoctocog alfa, BIVV001
Swedish Orphan Biovitrum, Syneos Health
Hemophilia A, Severe
05/26
05/26
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer

Recruiting
3
1170
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
08/27
08/27
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Recruiting
3
250
Europe, US, RoW
Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu®
Daiichi Sankyo, AstraZeneca
Breast Cancer
10/27
10/27
Tropion-Lung08, NCT05215340 / 2021-002555-10: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L metastatic NSCLC (based on TROPION Lung08 trial)
Jan 2024 - Dec 2024: Data from TROPION-Lung08 trial for advanced or metastatic NSCLC
Recruiting
3
740
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Non Small Cell Lung Cancer
02/28
04/28
 

Download Options